Depomed Inc (DEPO) 20.84 $DEPO Drug Makers Stoc
Post# of 273333
Posted On: 09/02/2016 3:09:01 PM
Depomed Inc (DEPO) 20.84 $DEPO
Drug Makers Stocks Under Scanner -- Amarin, Depomed, United Therapeutics, and Sucampo Pharma
PR Newswire - Tue Aug 16, 6:40AM CDT
In today's pre-market research, Stock-Callers.com follows four Drug Manufacturing equities, namely, Amarin Corp. PLC (NASDAQ: AMRN), Depomed Inc. (NASDAQ: DEPO), United Therapeutics Corp. (NASDAQ: UTHR), and Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP). Global prescription drug sales are expected to increase 3% this year despite drug-price debates and cost-control pressures. You can access of our complimentary research reports on these stocks now at:
UTHR: 122.73 (-0.48), AMRN: 2.95 (+0.16), SCMP: 11.11 (+0.01), DEPO: 20.84 (+0.24)
SmarTrend Watching for Potential Pullback in Shares of Depomed After 5.68% Gain
Comtex SmarTrend(R) - Thu Aug 04, 1:43PM CDT
Depomed (NASDAQ
EPO) traded in a range yesterday that spanned from a low of $19.15 to a high of $21.46. Yesterday, the shares gained 5.7%, which took the trading range above the 3-day high of $19.58 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
DEPO: 20.84 (+0.24)
Depomed Reports Second Quarter 2016 Financial Results
GlobeNewswire - Wed Aug 03, 3:16PM CDT
- Second Quarter Revenues of $117 million, 23% over 2Q 2015 -
DEPO: 20.84 (+0.24)
Downgrade Alert for Depomed (DEPO)
Comtex SmarTrend(R) - Thu Jul 28, 3:29AM CDT
Depomed (NASDAQEPO) was downgraded from Overweight to Neutral at Piper Jaffray today. The stock closed yesterday at $18.70 on volume of 1.2 million shares, below average daily volume of 2.2 million. Depomed (NASDAQEPO) has potential upside of 56.0% based on a current price of $18.70 and analysts' consensus price target of $29.17. The stock should hit resistance at its 200-day moving average (MA) of $19.87, as well as support at its 50-day MA of $15.49.
DEPO: 20.84 (+0.24)
Depomed to Report Second Quarter Fiscal Year 2016 Financial Results on Wednesday, August 3, 2016
GlobeNewswire - Wed Jul 27, 3:08PM CDT
Depomed, Inc. (NASDAQEPO) today announced that it will release second quarter fiscal year 2016 financial results after the close of market, Wednesday, August 3, 2016. The Company will host a conference call beginning at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss its results.
DEPO: 20.84 (+0.24)
Featured Research Report on Drug Manufacturers Stocks
ACCESSWIRE - Tue Jun 14, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 14, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Drug Manufacturers-Other industry. Companies recently under review include Ionis Pharma, Depomed, Amarin, and United Therapeutics. Register with us now for your free membership and see our complete reports on these equities at:
UTHR: 122.73 (-0.48), AMRN: 2.95 (+0.16), DEPO: 20.84 (+0.24), IONS: 29.54 (-0.50)
Depomed Issues Statement in Response to Starboard's Press Release
GlobeNewswire - Thu May 26, 10:17AM CDT
Depomed, Inc. (NASDAQEPO) ("Depomed" or the "Company"
today issued the following statement in response to Starboard Value LP's ("Starboard" latest press release.
DEPO: 20.84 (+0.24)
Starboard Delivers Letter to Depomed Shareholders
PR Newswire - Thu May 26, 8:08AM CDT
Starboard Value LP (together with its affiliates, "Starboard", one of the largest shareholders of Depomed, Inc. (NASDAQ: DEPO) with an ownership interest in approximately 9.9% of Depomed's outstanding shares, today announced it has delivered an open letter to Depomed shareholders and intends to recommence the process for calling a Special Meeting of Depomed shareholders for removing and replacing the current Depomed Board of Directors with a modified slate of six highly qualified director nominees.
DEPO: 20.84 (+0.24)
Cebranopadol Data Presented at World Institute of Pain Congress Highlight Clinically Significant Reductions in Pain, Low Abuse Deterrent Potential and a Favorable Respiratory Profile
GlobeNewswire - Mon May 23, 7:00AM CDT
Depomed, Inc. (NASDAQEPO) today announced that clinical data from Phase IIb trials of cebranopadol in chronic lower back pain (cLBP) and diabetic peripheral neuropathy (DPN) as well as from the human abuse potential and respiratory depression studies conducted by Grunenthal GmbH ("Grunenthal" were presented this weekend at the 8th World Congress of the World Institute of Pain (WIP) in New York, New York. Cebranopadol is a novel, first-in-class analgesic in development for the treatment of moderate to severe chronic nociceptive and neuropathic pain. In December 2015, Depomed acquired the U.S. and Canadian rights to cebranopadol from Grunenthal.
DEPO: 20.84 (+0.24)
Depomed Announces District Court Order Extending Stay in NUCYNTA ANDA Litigation
GlobeNewswire - Wed May 18, 3:45PM CDT
Depomed, Inc. (NasdaqEPO) today announced that on May 18, 2016, Judge Claire C. Cecchi of the United States District Court for the District of New Jersey entered an order enjoining any of Actavis Elizabeth LLC, Actavis LLC and Actavis Inc. (collectively, "Actavis", Alkem Laboratories Limited and Ascend Laboratories (together, "Alkem", Roxane Laboratories, Inc. ("Roxane", and Watson Laboratories, Inc. ("Watson" from marketing generic versions of any of NUCYNTA, NUCYNTA ER or NUCYNTA oral solution prior to the Court's issuance of a decision in the pending patent litigation. The U.S. patents asserted in the consolidated action are: RE39,593; 7,994,364; and 8,536,130, which currently expire on August 5, 2022, June 27, 2025, and September 22, 2028, respectively. An additional six months of patent protection is expected for these patents upon issuance of pediatric exclusivity from the FDA. Judge Cecchi's order states that she expects to render a decision on this matter no later than September 30, 2016.
DEPO: 20.84 (+0.24)
Depomed Announces Presentation of Cebranopadol Data at World Institute of Pain Congress
GlobeNewswire - Mon May 16, 7:00AM CDT
Depomed, Inc. (NASDAQEPO) today announced that clinical data from two Phase IIb trials as well as human abuse potential and respiratory depression studies conducted by Grunenthal GmbH ("Grunenthal" will be presented at the 8th World Congress of the World Institute of Pain (WIP) to be held May 20-23, 2016 at the New York Hilton Hotel in New York, New York. Cebranopadol is a novel, first-in-class analgesic in development for the treatment of moderate to severe chronic nociceptive and neuropathic pain. In December 2015, Depomed acquired the U.S. and Canadian rights to cebranopadol from Grunenthal.
DEPO: 20.84 (+0.24)
Upgrade Alert for Depomed (DEPO)
Comtex SmarTrend(R) - Tue May 10, 3:45AM CDT
Depomed (NASDAQEPO) was upgraded from Neutral to Buy at Mizuho today. The stock closed yesterday at $17.85 on volume of 4.4 million shares, above average daily volume of 2.2 million. There is potential upside of 63.4% for shares of Depomed based on a current price of $17.85 and an average consensus analyst price target of $29.17. Depomed shares should encounter resistance at the 200-day moving average (MA) of $19.87 and support at the 50-day MA of $15.49.
DEPO: 20.84 (+0.24)
Depomed reports 1Q loss
Automated Insights - Thu May 05, 4:34PM CDT
NEWARK, Calif. (AP) _ Depomed Inc. (DEPO) on Thursday reported a loss of $20.9 million in its first quarter.
DEPO: 20.84 (+0.24)
Depomed Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:00PM CDT
- First Quarter Revenues of $105M, up 225% over 1Q 2015 -
DEPO: 20.84 (+0.24)
What Caused DepoMed's Shares to Skyrocket 20.9% In April
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 11:40AM CDT
SOURCE: FLICKR USER STOCKMONKEYS.COM. What: After activist investor Starboard Value LP took a nearly 10% stake in DepoMed , the company's shares soared 20.9% last month, according to data from S&P Global Market Intelligence . So what:...
HZNP: 17.83 (-0.79), DEPO: 20.84 (+0.24)
Depomed to Present at Healthcare Conferences in May
GlobeNewswire - Tue May 03, 7:00AM CDT
Depomed, Inc. (NASDAQEPO) today announced that it will be presenting at the following healthcare conferences during the month of May.
DEPO: 20.84 (+0.24)
Depomed to Report First Quarter Fiscal Year 2016 Financial Results on Thursday, May 5, 2016
GlobeNewswire - Thu Apr 28, 7:00AM CDT
Depomed, Inc. (NASDAQEPO) today announced that it will release first quarter fiscal year 2016 financial results after the close of market, Thursday, May 5, 2016. The Company will host a conference call beginning at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss its results.
DEPO: 20.84 (+0.24)
4 Bargain Stocks You Can Buy Today
Todd Campbell, Jason Hall, Andrés Cardenal, and Steve Symington, The Motley Fool - Motley Fool - Wed Apr 27, 11:16AM CDT
Image source: Flickr user Elliott Brown. The market is always offering up stocks in its bargain bin, but that doesn't necessarily mean every stock that's on sale is worth buying. We asked some of our top Motley Fool contributors to weigh in with...
IBM: 159.47 (-0.07), DEPO: 20.84 (+0.24), CLNE: 4.58 (-0.03), PCLN: 1,419.55 (+0.96)
Depomed gives Starboard chance for meeting to replace board
By The Associated Press - AP - Mon Apr 25, 10:02AM CDT
Depomed is taking another step to avoid the pain of a protracted fight with activist investor Starboard Value over control of the drugmaker.
DEPO: 20.84 (+0.24), DRI: 62.27 (+0.38)
Drug Makers Stocks Under Scanner -- Amarin, Depomed, United Therapeutics, and Sucampo Pharma
PR Newswire - Tue Aug 16, 6:40AM CDT
In today's pre-market research, Stock-Callers.com follows four Drug Manufacturing equities, namely, Amarin Corp. PLC (NASDAQ: AMRN), Depomed Inc. (NASDAQ: DEPO), United Therapeutics Corp. (NASDAQ: UTHR), and Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP). Global prescription drug sales are expected to increase 3% this year despite drug-price debates and cost-control pressures. You can access of our complimentary research reports on these stocks now at:
UTHR: 122.73 (-0.48), AMRN: 2.95 (+0.16), SCMP: 11.11 (+0.01), DEPO: 20.84 (+0.24)
SmarTrend Watching for Potential Pullback in Shares of Depomed After 5.68% Gain
Comtex SmarTrend(R) - Thu Aug 04, 1:43PM CDT
Depomed (NASDAQ
EPO) traded in a range yesterday that spanned from a low of $19.15 to a high of $21.46. Yesterday, the shares gained 5.7%, which took the trading range above the 3-day high of $19.58 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. DEPO: 20.84 (+0.24)
Depomed Reports Second Quarter 2016 Financial Results
GlobeNewswire - Wed Aug 03, 3:16PM CDT
- Second Quarter Revenues of $117 million, 23% over 2Q 2015 -
DEPO: 20.84 (+0.24)
Downgrade Alert for Depomed (DEPO)
Comtex SmarTrend(R) - Thu Jul 28, 3:29AM CDT
Depomed (NASDAQ
EPO) was downgraded from Overweight to Neutral at Piper Jaffray today. The stock closed yesterday at $18.70 on volume of 1.2 million shares, below average daily volume of 2.2 million. Depomed (NASDAQEPO) has potential upside of 56.0% based on a current price of $18.70 and analysts' consensus price target of $29.17. The stock should hit resistance at its 200-day moving average (MA) of $19.87, as well as support at its 50-day MA of $15.49. DEPO: 20.84 (+0.24)
Depomed to Report Second Quarter Fiscal Year 2016 Financial Results on Wednesday, August 3, 2016
GlobeNewswire - Wed Jul 27, 3:08PM CDT
Depomed, Inc. (NASDAQ
EPO) today announced that it will release second quarter fiscal year 2016 financial results after the close of market, Wednesday, August 3, 2016. The Company will host a conference call beginning at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss its results. DEPO: 20.84 (+0.24)
Featured Research Report on Drug Manufacturers Stocks
ACCESSWIRE - Tue Jun 14, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 14, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Drug Manufacturers-Other industry. Companies recently under review include Ionis Pharma, Depomed, Amarin, and United Therapeutics. Register with us now for your free membership and see our complete reports on these equities at:
UTHR: 122.73 (-0.48), AMRN: 2.95 (+0.16), DEPO: 20.84 (+0.24), IONS: 29.54 (-0.50)
Depomed Issues Statement in Response to Starboard's Press Release
GlobeNewswire - Thu May 26, 10:17AM CDT
Depomed, Inc. (NASDAQ
EPO) ("Depomed" or the "Company" today issued the following statement in response to Starboard Value LP's ("Starboard" latest press release. DEPO: 20.84 (+0.24)
Starboard Delivers Letter to Depomed Shareholders
PR Newswire - Thu May 26, 8:08AM CDT
Starboard Value LP (together with its affiliates, "Starboard"
, one of the largest shareholders of Depomed, Inc. (NASDAQ: DEPO) with an ownership interest in approximately 9.9% of Depomed's outstanding shares, today announced it has delivered an open letter to Depomed shareholders and intends to recommence the process for calling a Special Meeting of Depomed shareholders for removing and replacing the current Depomed Board of Directors with a modified slate of six highly qualified director nominees. DEPO: 20.84 (+0.24)
Cebranopadol Data Presented at World Institute of Pain Congress Highlight Clinically Significant Reductions in Pain, Low Abuse Deterrent Potential and a Favorable Respiratory Profile
GlobeNewswire - Mon May 23, 7:00AM CDT
Depomed, Inc. (NASDAQ
EPO) today announced that clinical data from Phase IIb trials of cebranopadol in chronic lower back pain (cLBP) and diabetic peripheral neuropathy (DPN) as well as from the human abuse potential and respiratory depression studies conducted by Grunenthal GmbH ("Grunenthal" were presented this weekend at the 8th World Congress of the World Institute of Pain (WIP) in New York, New York. Cebranopadol is a novel, first-in-class analgesic in development for the treatment of moderate to severe chronic nociceptive and neuropathic pain. In December 2015, Depomed acquired the U.S. and Canadian rights to cebranopadol from Grunenthal. DEPO: 20.84 (+0.24)
Depomed Announces District Court Order Extending Stay in NUCYNTA ANDA Litigation
GlobeNewswire - Wed May 18, 3:45PM CDT
Depomed, Inc. (Nasdaq
EPO) today announced that on May 18, 2016, Judge Claire C. Cecchi of the United States District Court for the District of New Jersey entered an order enjoining any of Actavis Elizabeth LLC, Actavis LLC and Actavis Inc. (collectively, "Actavis", Alkem Laboratories Limited and Ascend Laboratories (together, "Alkem", Roxane Laboratories, Inc. ("Roxane", and Watson Laboratories, Inc. ("Watson" from marketing generic versions of any of NUCYNTA, NUCYNTA ER or NUCYNTA oral solution prior to the Court's issuance of a decision in the pending patent litigation. The U.S. patents asserted in the consolidated action are: RE39,593; 7,994,364; and 8,536,130, which currently expire on August 5, 2022, June 27, 2025, and September 22, 2028, respectively. An additional six months of patent protection is expected for these patents upon issuance of pediatric exclusivity from the FDA. Judge Cecchi's order states that she expects to render a decision on this matter no later than September 30, 2016. DEPO: 20.84 (+0.24)
Depomed Announces Presentation of Cebranopadol Data at World Institute of Pain Congress
GlobeNewswire - Mon May 16, 7:00AM CDT
Depomed, Inc. (NASDAQ
EPO) today announced that clinical data from two Phase IIb trials as well as human abuse potential and respiratory depression studies conducted by Grunenthal GmbH ("Grunenthal" will be presented at the 8th World Congress of the World Institute of Pain (WIP) to be held May 20-23, 2016 at the New York Hilton Hotel in New York, New York. Cebranopadol is a novel, first-in-class analgesic in development for the treatment of moderate to severe chronic nociceptive and neuropathic pain. In December 2015, Depomed acquired the U.S. and Canadian rights to cebranopadol from Grunenthal. DEPO: 20.84 (+0.24)
Upgrade Alert for Depomed (DEPO)
Comtex SmarTrend(R) - Tue May 10, 3:45AM CDT
Depomed (NASDAQ
EPO) was upgraded from Neutral to Buy at Mizuho today. The stock closed yesterday at $17.85 on volume of 4.4 million shares, above average daily volume of 2.2 million. There is potential upside of 63.4% for shares of Depomed based on a current price of $17.85 and an average consensus analyst price target of $29.17. Depomed shares should encounter resistance at the 200-day moving average (MA) of $19.87 and support at the 50-day MA of $15.49. DEPO: 20.84 (+0.24)
Depomed reports 1Q loss
Automated Insights - Thu May 05, 4:34PM CDT
NEWARK, Calif. (AP) _ Depomed Inc. (DEPO) on Thursday reported a loss of $20.9 million in its first quarter.
DEPO: 20.84 (+0.24)
Depomed Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:00PM CDT
- First Quarter Revenues of $105M, up 225% over 1Q 2015 -
DEPO: 20.84 (+0.24)
What Caused DepoMed's Shares to Skyrocket 20.9% In April
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 11:40AM CDT
SOURCE: FLICKR USER STOCKMONKEYS.COM. What: After activist investor Starboard Value LP took a nearly 10% stake in DepoMed , the company's shares soared 20.9% last month, according to data from S&P Global Market Intelligence . So what:...
HZNP: 17.83 (-0.79), DEPO: 20.84 (+0.24)
Depomed to Present at Healthcare Conferences in May
GlobeNewswire - Tue May 03, 7:00AM CDT
Depomed, Inc. (NASDAQ
EPO) today announced that it will be presenting at the following healthcare conferences during the month of May. DEPO: 20.84 (+0.24)
Depomed to Report First Quarter Fiscal Year 2016 Financial Results on Thursday, May 5, 2016
GlobeNewswire - Thu Apr 28, 7:00AM CDT
Depomed, Inc. (NASDAQ
EPO) today announced that it will release first quarter fiscal year 2016 financial results after the close of market, Thursday, May 5, 2016. The Company will host a conference call beginning at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss its results. DEPO: 20.84 (+0.24)
4 Bargain Stocks You Can Buy Today
Todd Campbell, Jason Hall, Andrés Cardenal, and Steve Symington, The Motley Fool - Motley Fool - Wed Apr 27, 11:16AM CDT
Image source: Flickr user Elliott Brown. The market is always offering up stocks in its bargain bin, but that doesn't necessarily mean every stock that's on sale is worth buying. We asked some of our top Motley Fool contributors to weigh in with...
IBM: 159.47 (-0.07), DEPO: 20.84 (+0.24), CLNE: 4.58 (-0.03), PCLN: 1,419.55 (+0.96)
Depomed gives Starboard chance for meeting to replace board
By The Associated Press - AP - Mon Apr 25, 10:02AM CDT
Depomed is taking another step to avoid the pain of a protracted fight with activist investor Starboard Value over control of the drugmaker.
DEPO: 20.84 (+0.24), DRI: 62.27 (+0.38)
(0)
(0)